Ipsen Stock

Ipsen EBITDA per Employee

The EBITDA per Employee of Ipsen (IPN.PA) as of Aug 9, 2026 is 128,517.31 EUR. In the previous year, EBITDA per Employee was 132,615.81 EUR — a change of -3.09% (lower).

EBITDA per Employee

128,517.31EUR

YoY

-3.09%

Last updated:

EBITDA per Employee of Ipsen is 2026 128,517.31 EUR. EBITDA per Employee of Ipsen was 2025 132,615.81 EUR. It decreases by -3.09% lower compared to the previous year.
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

EBITDA per Employee of Ipsen is 128,517.31 EUR in 2026.

EBITDA per Employee of Ipsen changed from 132,615.81 EUR to 128,517.31 EUR, representing a -3.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Ipsen since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Ipsen historically and in real time.

Access this data via the Eulerpool API

Workforce — Ipsen

All Key Metrics — Ipsen